Skip Ribbon Commands
Skip to main content

QuiremScout™

Microspheres

Description

SELECT THE RIGHT PATIENTS, WITH CONFIDENCE

QuiremScoutTM: the first SIRT work-up product that uses the same technology as the therapeutic
microspheres, to optimize patient selection and advance treatment planning

Characteristics

QuiremScoutTM:
  • Contains the same microspheres as QuiremSpheresTM(1)
  • has been shown to be safe in a study of 82 patients (2,3)
  • has been shown to be a better predictor for lung shunt and intrahepatic distribution than 99mTc-MAA (4,5)
  • has been shown to be more accurate at treatment planning than 99mTc-MAA, ensuring the right patients are identified for SIRT (6–8)

Preparation

Video instructions

 
 



Clinical evidence

See all clinical evidence

General specifications

​Characteristics
​99mTc-MAA
​QuiremScoutTM
​QuiremSpheresTM
Particle Morphology​MAA.JPG
microsphere.JPG
microsphere.JPG
​Material
​MAA
​PLLA
​PLLA
​Particle size (µm)
​1 - 150
​30 (15-60)
​30 (15-60)
​Number of particles (million)
​0.2 - 1.2
​3
​30
​Gamma energy
​141 keV
​81 keV
​81 keV

QuiremScoutTM is a product manufactured by Quirem Medical B.V and has CE-mark.

QuiremScoutTM is not available for sales in all countries. This information is provided only in respect to markets where the product is approved and cleared. 

QuiremScoutTM is not FDA cleared in the US. 

Item specifications

​Item reference
​Material description
​Description
​QS-S001

​QuiremScout®

​V-vial containing a small quantity of low-dose holmium-166 microspheres
​QS-C001
​Customer kit

​Set of re-usable administration box and accessories for administration of QuiremSpheres®

​QS-D001
​Delivery set

​Set of sterile single-use tube lines for administration of QuiremSpheres® (in a carton of 6 pieces)


References

1 QuiremScoutTM 166Ho-Scout – Instruction for use
2 Braat et al. Eur Radiol 2018;28:920–28
3 Prince et al. J Nucl Med 2015;56:817–23
4. Elschot et al. Eur J Nucl Med Mol Imaging 2014;41:1965–75
5. Dassen et al. Presented at CIRSE 2018. Abstract available at: https://library.cirse.org/cirse2018/crs/the-predictive-value-of-theintrahepatic-
distribution-of-99mtc-macroaggregated-albumin-and-holmium-166-scout-dose-prior-to-holmium-166-radioembolization
6. Grosche-Schlee et al. QuiremScoutTM case study. Available at: https://www.terumo-europe.com/en-emea/clinical-program/Clinical%20
Data/E_Clinical_Case_Studies_QuiremScout_LR.PDF#search=SIRT%20case%20study
7. Smits et al. Eur J Nucl Med Mol Imaging 2020;47:798–806
8. Chiesa and Maccauro. Eur J Nucl Med Mol Imaging 2020;47:744–47

Do you need more info about this product?

Our sales representatives are here for you.

Contact us
Send us a message
 
I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*
I wish to receive information and marketing updates from Terumo.
* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Didn't find your product?

Consult our products in our Product Index

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public


For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.